Digital Desk, New Delhi. 84-year-old Mohabbat Singh from Haryana was given an antibody cocktail which was also given to former US President Donald Trump. Mohabbat Singh is the first patient in the country who was given the antibody cocktail drug of Roche India and Cipla. After delivering the cocktail, Singh was kept under observation and then discharged from the hospital. The monoclonal antibody cocktail is being described as a game changer in the fight against Kovid. Studies have shown that 80% of patients taking this drug did not require hospitalization.
Dr. Arvinder S. Soin reports that the US Food and Drug Administration’s (FDA)-authorized three-specific drug (monoclonal antibody drug) and India’s Central Drug Standard Control Organization (CDSCO)-authorized drug can ‘root out kovid infection’ is. Dr. Soin stated that the drug should be given immediately after the patient’s positive test and certainly in the first week of infection. This can prevent serious illnesses and deaths.
Dr. Nirmal K Ganguly, former Director General of ICMR, said, ‘Since this (monoclonal antibody) is a highly expensive product, do not use it for all covid-infected individuals. Use it only for people with severe infections who are hospitalized. Dr. Raman R. Gangakhedkar, former chief scientist of ICMR, said, in the next few days, we will come to know how monoclonal antibodies are working against Kovid and its variants.
Dr. Ganguly told ANI that the cost of monoclonal antibody therapy can be reduced if a very efficient system is developed for its manufacture. The former DG of ICMR stated, nowadays monoclonal antibodies are produced through the mammalian cell culture system and can be produced in large quantities through fermentation technology.
Therapy is a cocktail of two monoclonal antibodies. Antibodies are proteins that the body produces to protect against any disease. Monoclonal antibodies are artificially made in a laboratory. It is prepared according to the fight against any disease. In any covid patient, normal antibodies develop only after 14 days of infection. But lab-produced antibodies work immediately in this drug.
Kasirivimab and imdevimab have been specifically formulated to act against the spike protein of the covid pandemic virus SARS-CoV-2. It blocks the attachment of the virus and then its entry into human cells. The dose of 600–600 mg of both antibodies is given in this cocktail. It can be stored at a temperature of 2–8 ° C.